Suganthi Sridhar, Katie Uhl, Basma Khudur, Bikash Mishra, Robert Smart and William Schroeder
Cancer is often referred to as being “immortal” because of high telomerase activity in these cells, which allows them to divide an infinite amount of times. BIBR-1532, (2-{[(2E)-3-(2Naphthyl)-2-butenoyl]amino}benzoic acid) is a known telomerase inhibitor that has undergone preclinical trials for the treatment of cancer. Based on the structure of BIBR-1532, three novel N- cinnamoyl substituted anthranilic acid derivatives (2-{[(2E)-3-(4 “ X ” phenyl)-2- propenoyl]amino}benzoic acids), similar to BIBR-1532 were synthesized. Their efficacies were tested against proliferative activity in metastatic prostate cancer cells, along with the known telomerase inhibitor BIBR-1532. Telomerase Repeat Amplification Protocol (TRAP) assays were performed on the compounds to confirm their antitelomerase activity. The results showed all three newly synthesized cinnamic derivatives have antiproliferative qualities equivalent to or better than BIBR-1532 (p=0.027) and overall all compounds were significantly lower than the control (p<0.0001). TRAP assays further confirmed that the compounds also exhibited anti-telomerase activity like BIBR-1532. The newly synthesized cinnamic acid derivatives of BIBR- 1532 all showed antiproliferative and antitelomerase activity. While these compounds were all tested against metastatic prostate cancer cells, these potential treatments have application in all types of cancers demonstrating high telomerase activity.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu